Diabetes and Risk of Non-Hodgkin's Lymphoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To examine the epidemiologic association between diabetes and risk of non-Hodgkin's lymphoma (NHL). RESEARCH DESIGN AND METHODS—We searched MEDLINE for observational studies on the association between diabetes and NHL in adults using the keywords “diabetes” and “lymphoma.” Prospective cohort studies that reported relative risks or standardized incidence ratios and case-control studies that reported odds ratios with 95% CIs were included. A random-effects model was used to combine results from the individual studies. RESULTS—A total of 15 manuscripts (reporting data from 5 prospective cohort and 11 case-control studies) met the inclusion criteria. Combining data from all studies, the risk ratio (RR) of developing NHL in patients with diabetes was 1.19 (95% CI 1.04–1.35). Based on prospective studies, patients with diabetes had an RR of developing NHL of 1.41 (1.07–1.88), without heterogeneity among studies (I2 = 34.3%; P > 0.10). Based on case-control studies, patients with diabetes had an RR of 1.12 (95% CI 0.95–1.31) of developing NHL compared with people without diabetes, with some heterogeneity among studies (I2 = 36.28%; P = 0.09). CONCLUSIONS—Diabetes is associated with a moderately increased risk of NHL, which is consistent with other reported associations between diabetes and malignancies. Future studies should focus on elucidating potential pathophysiologic links between diabetes and NHL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes
Pickup, J. C. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.813 · Cited by 1,414 · cited 1×
“Individuals with diabetes are believed to have altered immune function and to be in a relatively immunodeficient state (8), which may contribute to the pathogenesis of lymphoproliferative disorders, such as NHL (9).”
BackgroundBax, L., Yu, L.-M., Ikeda, N., Tsuruta, H., & Moons, K. G. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-50 · Cited by 514
Cited by
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms
Arcidiacono, B., Iiritano, S., Nocera, A., Possidente, K., Nevolo, M. T., Ventura, V., Foti, D., Chiefari, E., & Brunetti, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/789174 · Cited by 606
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Metformin: Taking away the candy for cancer?
Jalving, M., Gietema, J. A., Lefrandt, J. D., Jong, S. D., Reyners, A. K. L., Gans, R. O. B., & Vries, E. G. E. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.012 · Cited by 380
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk
Clayton, P. E., Banerjee, I., Murray, P. G., & Renehan, A. G. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.171 · Cited by 364
Metformin in cancer: translational challenges
Dowling, R. J. O., Niraula, S., Stambolic, V., & Goodwin, P. J. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0007 · Cited by 355
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
“Furthermore, several other studies have linked diabetes, in particular type II diabetes, to development of non-Hodgkin’s lymphoma (49, 50), pancreatic (51), colorectal (52), bladder (53) and endometrial (54) cancer.”
BackgroundHarding, J. L., Shaw, J. E., Peeters, A., Cartensen, B., & Magliano, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1996 · Cited by 286
Diabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & Selagamsetty, R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 275
on behalf of the Diabetes and Cancer Research Consortium, Johnson, J. A., Carstensen, B., Witte, D., Bowker, S. L., Lipscombe, L., & Renehan, A. G. (2012) · Diabetologia · doi:10.1007/s00125-012-2525-1 · Cited by 260
Metadata
- Authors
- Mitri, J., Castillo, J., & Pittas, A. G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-12-01
- Volume
- 31
- Issue
- 12
- Pages
- 2391-2397
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2061867878
- Cited by
- 140
- References
- 4
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.